PFG Investments LLC Acquires 227 Shares of Stryker Corporation $SYK

PFG Investments LLC grew its holdings in Stryker Corporation (NYSE:SYK) by 5.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,782 shares of the medical technology company’s stock after acquiring an additional 227 shares during the period. PFG Investments LLC’s holdings in Stryker were worth $1,892,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Consolidated Portfolio Review Corp lifted its position in Stryker by 4.2% in the second quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after buying an additional 26 shares during the last quarter. Sunflower Bank N.A. lifted its position in Stryker by 4.0% in the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after buying an additional 27 shares during the last quarter. Pitti Group Wealth Management LLC lifted its position in Stryker by 3.2% in the second quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after buying an additional 27 shares during the last quarter. Continuum Advisory LLC lifted its position in Stryker by 5.8% in the first quarter. Continuum Advisory LLC now owns 532 shares of the medical technology company’s stock valued at $198,000 after buying an additional 29 shares during the last quarter. Finally, Oakworth Capital Inc. lifted its position in Stryker by 0.5% in the first quarter. Oakworth Capital Inc. now owns 6,133 shares of the medical technology company’s stock valued at $2,283,000 after buying an additional 29 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Down 1.5%

Shares of NYSE:SYK opened at $364.07 on Thursday. The firm’s 50 day moving average price is $384.08 and its 200 day moving average price is $379.01. The stock has a market cap of $139.19 billion, a price-to-earnings ratio of 48.22, a price-to-earnings-growth ratio of 2.66 and a beta of 0.95. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio is currently 44.50%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Redburn Partners set a $420.00 target price on shares of Stryker in a research report on Thursday, September 18th. Wells Fargo & Company increased their price target on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Rothschild Redb raised shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Finally, Rothschild & Co Redburn initiated coverage on shares of Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target on the stock. Fourteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $430.33.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.